arrow
D

Domenica Lorusso

università cattolica del sacro cuore
H指数:77
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

BEHOLD-1 and -2: Phase 1/2 Randomized Studies Evaluating the B7 Homolog 4 Protein–Targeted Antibody-Drug Conjugate Mocertatug Rezetecan in Patients With Solid Tumors, Including Endometrial and Ovarian Cancers

BEHOLD-1和-2:评估B7同源4蛋白靶向抗体-药物偶联物Mocertatug Rezetecan在实体瘤患者中疗效的1/2期随机研究,包括子宫内膜癌和卵巢癌

2026-09-070
PRE
Challenges in the use of the European Society for Radiotherapy and Oncology–European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer

使用欧洲放射肿瘤学会–欧洲癌症研究和治疗组织寡转移性疾病分类系统在卵巢癌中的挑战

2026-08-240
PRE
Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research

第一届妇科肿瘤学组宫颈癌共识会议的临床研究共识声明

2026-07-270
PRE
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

PRIMA/ENGOT-OV26/GOG-3012试验中 niraparib 一线维持治疗新诊断晚期卵巢癌患者的患者报告结局更新及疾病进展对健康相关生活质量的影响

2026-07-010
OAAI
Somatic BRCA1 and BRCA2 detection in Homologous Recombination Deficiency testing: concordance of four sequencing workflows with the Myriad myChoice® companion diagnostic

体细胞BRCA1和BRCA2检测在同源重组缺陷测试中的应用:四种测序工作流与Myriad myChoice®伴随诊断的一致性

2026-06-200
PRE
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses

曲妥珠单抗德鲁替康在DESTINY-PanTumor02研究中对HER2表达妇科癌症的抗肿瘤活性、安全性和探索性生物标志物分析

2026-05-010
PRE
Final overall survival (OS) results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223)

ROSELLA三期试验的最终总生存期(OS)结果:relacorilant联合nab-紫杉醇对比nab-紫杉醇单药治疗铂耐药卵巢癌(PROC)患者的疗效(GOG-3073,ENGOT-ov72,APGOT-Ov10和LACOG-0223)

2026-04-230
PRE
Lenvatinib Plus Pembrolizumab in Participants With Advanced or Recurrent Endometrial Cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 Post-(Neo)Adjuvant Therapy Outcomes

Lenvatinib联合Pembrolizumab在晚期或复发性子宫内膜癌患者中的应用:Study 309/KEYNOTE-775和ENGOT-en9/LEAP-001术后(新辅助)治疗结局

2026-04-120
PRE
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial

多模态泛肿瘤细胞游离DNA分析用于卵巢癌微小残留病灶检测和风险分层:MITO16a/MaNGO-OV2试验结果

2026-02-260
OAAI
Particle beam re-irradiation in oligorecurrent gynecological malignancies

少发妇科恶性肿瘤的粒子束再照射

2026-01-270
PRE
Surgical Timing in Advanced Ovarian Cancer During the TRUST Trial Era: A Systematic Review, Meta-Analysis and Study-Level Meta-regression of Randomized Controlled Trials

TRUST试验时期晚期卵巢癌的手术时机:一项系统评价、随机对照试验的Meta分析及研究水平的Meta回归

2025-12-180
OAAI
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析

2025-12-050
OAAI
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial

来曲唑用于激素受体阳性低级别卵巢癌:一项III期试验的初步毒性结果

2025-12-010
PRE
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial

肿瘤浸润性白细胞作为接受贝伐珠单抗治疗的卵巢癌患者的预后生物标志物:来自IV期MITO16A/MaNGO OV-2临床 trial 的结果

2025-11-170
OAAI
Neoadjuvant Chemotherapy Followed by Interval Surgery versus Primary Debulking Surgery in FIGO Stage III–IV Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis

新辅助化疗后间隔手术与初始肿瘤细胞减灭术在FIGO III–IV期上皮性卵巢癌中的应用比较:一项系统评价和Meta分析

2025-11-150
PRE
Corrigendum to “First-line treatments for advanced or recurrent endometrial cancer: Systemic literature review of clinical evidence” [Crit. Rev. Oncol./Hematol. 206 (2025) 104555]

勘误:“晚期或复发性子宫内膜癌的一线治疗:临床证据的系统文献综述”[Crit. Rev. Oncol./Hematol. 206 (2025) 104555]

2025-08-120
PRE